KindlyMD (NASDAQ:NAKA) Trading 15.8% Higher - Still a Buy?

Key Points

• KindlyMD's stock experienced a 15.8% increase, reaching a trading price of $5.28 after closing at $4.56.
• Wall Street analysts have given KindlyMD a consensus rating of "Buy" with a target price of $8.00, according to a report from Maxim Group.
• The company reported a negative EPS of ($0.34) and a market capitalization of $3.23 billion, despite its focus on holistic pain management and combating the opioid crisis.

KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report) traded up 15.8% during mid-day trading on Tuesday . The company traded as high as $5.42 and last traded at $5.28. 2,122,911 shares traded hands during mid-day trading, a decline of 29% from the average session volume of 2,995,563 shares. The stock had previously closed at $4.56.

Wall Street Analysts Forecast Growth

Separately, Maxim Group assumed coverage on KindlyMD in a research report on Wednesday, September 3rd. They issued a "buy" rating and a $8.00 target price for the company. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $8.00.

KindlyMD Stock Up 88.2%

The business's 50 day moving average is $9.81. The company has a market capitalization of $3.23 billion, a PE ratio of -9.98 and a beta of 34.05.

KindlyMD (NASDAQ:NAKA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.34) EPS for the quarter. The company had revenue of $0.41 million for the quarter. KindlyMD had a negative net margin of 244.00% and a negative return on equity of 131.09%.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.